Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The state of the art of PROTAC technologies for drug discovery
Chao Wang, Cangxin Zheng, Han Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 235, pp. 114290-114290
Closed Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Molecular hybridization: a powerful tool for multitarget drug discovery
Pedro de Sena Murteira Pinheiro, Lucas Silva Franco, Tadeu L. Montagnoli, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 451-470
Closed Access | Times Cited: 28
Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 12
Research in the Field of Drug Design and Development
Grażyna Biała, Ewa Kędzierska, Marta Kruk-Słomka, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1283-1283
Open Access | Times Cited: 23
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, et al.
Molecular Diversity (2023) Vol. 28, Iss. 1, pp. 309-333
Open Access | Times Cited: 21
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 411-411
Open Access | Times Cited: 20
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 19
PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review
Chao Wang, Yujing Zhang, Wanpeng Yu, et al.
International Journal of Biological Macromolecules (2024) Vol. 261, pp. 129864-129864
Closed Access | Times Cited: 6
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Binbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 6906-6921
Closed Access | Times Cited: 6
Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020
Yanqing Liu, Jie Chen, Xiang Li, et al.
Pharmacological Research (2025) Vol. 212, pp. 107577-107577
Open Access
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Research Progress in DNA Damage Response (DDR)-Targeting Modulators: from Hits to Clinical Candidates
Binbin Cheng, Zongbao Ding, Yun Hong, et al.
European Journal of Medicinal Chemistry (2025), pp. 117347-117347
Closed Access
Advancing targeted protein degradation for metabolic diseases therapy
Qianqian Zhou, Haitao Xiao, Fan Yang, et al.
Pharmacological Research (2022) Vol. 188, pp. 106627-106627
Open Access | Times Cited: 30
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3135-3172
Closed Access | Times Cited: 18
Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization
Cangxin Zheng, Chao Wang, Dan Sun, et al.
European Journal of Medicinal Chemistry (2023) Vol. 255, pp. 115393-115393
Closed Access | Times Cited: 18
The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases
Yi‐Ru Bai, Weiguang Yang, Xuehui Hou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115606-115606
Closed Access | Times Cited: 17
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
Bowen Zhang, Chang Liu, Zhenqian Yang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 11158-11186
Closed Access | Times Cited: 16
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance
Huanjie Zhu, Jin Wang, Qingqing Zhang, et al.
Pharmacology & Therapeutics (2023) Vol. 244, pp. 108371-108371
Closed Access | Times Cited: 15
Targeted protein degradation in drug development: Recent advances and future challenges
Jian H. Song, Mingzheng Hu, Jun Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115839-115839
Closed Access | Times Cited: 14
Targeting epigenetic modifications in Parkinson's disease therapy
Dan Zhang, Jifa Zhang, Yuxi Wang, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1748-1777
Closed Access | Times Cited: 13
Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction
Ru Si, Ping Hai, Yongbiao Zheng, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115497-115497
Closed Access | Times Cited: 12
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 11
Research progress of PROTACs for neurodegenerative diseases therapy
Zhifang Cai, Zunhua Yang, Huilan Li, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107386-107386
Closed Access | Times Cited: 3
Targeted degradation of LRG1 to attenuate renal fibrosis
Linyao Fan, Yingqiu Qi, Xi Yang, et al.
Asian Journal of Pharmaceutical Sciences (2024) Vol. 19, Iss. 4, pp. 100941-100941
Open Access | Times Cited: 3
Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease
Yan Li, Shuxian Lin, Zhicheng Gu, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 76, pp. 129015-129015
Closed Access | Times Cited: 20
Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
Yan Li, Zhicheng Gu, Shuxian Lin, et al.
Brain Sciences (2022) Vol. 12, Iss. 5, pp. 672-672
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top